Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 24378319)

1.

Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series.

Nooka AK, Harvey RD, Langston A, Collins H, Lonial S, Kaufman JL.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):e59-63. doi: 10.1016/j.clml.2013.11.007. Epub 2013 Nov 15. No abstract available.

PMID:
24378319
2.

Tandem bone marrow transplantation in multiple myeloma.

Chng WJ.

N Engl J Med. 2004 Apr 1;350(14):1466-7; author reply 1466-7. No abstract available.

PMID:
15074003
3.

Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma.

Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH.

Leuk Lymphoma. 2012 Jan;53(1):118-22. doi: 10.3109/10428194.2011.606942. Epub 2011 Aug 24.

PMID:
21780997
4.

The role of transplant in multiple myeloma.

Barlogie B.

Clin Adv Hematol Oncol. 2005 Aug;3(8):604-6. Review. No abstract available.

PMID:
16167043
5.

Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial.

Abidi MH, Agarwal R, Ayash L, Deol A, Al-Kadhimi Z, Abrams J, Cronin S, Ventimiglia M, Lum L, Zonder J, Ratanatharathorn V, Uberti J.

Biol Blood Marrow Transplant. 2012 Sep;18(9):1455-61. doi: 10.1016/j.bbmt.2012.03.010. Epub 2012 Mar 24.

6.
7.

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.

Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, Jaubert J, Fuzibet JG, François S, Benboubker L, Monconduit M, Voillat L, Macro M, Berthou C, Dorvaux V, Pignon B, Rio B, Matthes T, Casassus P, Caillot D, Najman N, Grosbois B, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome.

Blood. 2002 Feb 1;99(3):731-5.

8.
9.

A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.

Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, Van Besien K, Shore T.

Biol Blood Marrow Transplant. 2013 May;19(5):831-7. doi: 10.1016/j.bbmt.2013.02.013. Epub 2013 Feb 20.

10.

Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure.

Tosi P, Zamagni E, Ronconi S, Benni M, Motta MR, Rizzi S, Tura S, Cavo M.

Leukemia. 2000 Jul;14(7):1310-3.

PMID:
10914557
11.
12.

[Autologous transplantation of peripheral hematopoietic cells in a patient with multiple myeloma and renal insufficiency].

Krejcí M, Doubek M, Adam Z, Hájek R, Vorlícek J, Mayer J.

Vnitr Lek. 1997 Nov;43(11):756-8. Czech.

PMID:
9650509
13.

Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma.

Vogl DT, Wang T, Pérez WS, Stadtmauer EA, Heitjan DF, Lazarus HM, Kyle RA, Kamble R, Weisdorf D, Roy V, Gibson J, Ballen K, Holmberg L, Bashey A, McCarthy PL, Freytes C, Maharaj D, Maiolino A, Vesole D, Hari P.

Biol Blood Marrow Transplant. 2011 Dec;17(12):1765-74. doi: 10.1016/j.bbmt.2011.05.005. Epub 2011 May 11.

14.

Analysis of outcome following allogeneic haemopoietic stem cell transplantation for myeloma using myeloablative conditioning--evidence for a superior outcome using melphalan combined with total body irradiation.

Hunter HM, Peggs K, Powles R, Rahemtulla A, Mahendra P, Cavenagh J, Littlewood T, Potter M, Hunter A, Pagliuca A, Williams CD, Cook G, Towlson K, Marks David I, Russell NH; Clinical Trials Committee of the British Society of Blood and Marrow Transplantation (BSBMT).

Br J Haematol. 2005 Feb;128(4):496-502.

PMID:
15686458
15.

Autologous hematopoietic stem-cell transplantation for multiple myeloma.

Harousseau JL, Moreau P.

N Engl J Med. 2009 Jun 18;360(25):2645-54. doi: 10.1056/NEJMct0805626. Review. No abstract available.

PMID:
19535803
16.

High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.

Pineda-Roman M, Barlogie B, Anaissie E, Zangari M, Bolejack V, van Rhee F, Tricot G, Crowley J.

Cancer. 2008 Apr 15;112(8):1754-64. doi: 10.1002/cncr.23327.

17.

Single-agent high-dose melphalan followed by peripheral blood stem cell (PBSC) in lymphoma patients: an effective, and well-tolerated conditioning regimen.

Magagnoli M, Castagna L, Bramanti S, Balzarotti M, Santoro A.

Bone Marrow Transplant. 2004 May;33(10):1067-8. No abstract available.

PMID:
15129236
18.
19.

Long-term outcome of autologous stem cell transplantation in light chain deposition disease.

Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N.

Nephrol Dial Transplant. 2008 Jun;23(6):2052-7. doi: 10.1093/ndt/gfm918. Epub 2008 Jan 4.

20.

Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

San Miguel JF, Lahuerta JJ, García-Sanz R, Alegre A, Bladé J, Martinez R, García-Laraña J, De La Rubia J, Sureda A, Vidal MJ, Escudero A, Pérez-Esquiza E, Conde E, García-Ruiz JC, Cabrera R, Caballero D, Moraleda JM, Leon A, Besalduch J, Hernandez MT, Rifon J, Hernandez F, Solano C, Palomera L, Parody R, Gonzalez JD, Mataix R, Maldonado J, Constela J, Carrera D, Bello JL, De Pablos JM, Pérez-Simón JA, Torres JP, Olanguren J, Prieto E, Acebede G, Peñarrubia MJ, Torres P, Díez-Martín JL, Rivas A, Sánchez JM, Díaz-Mediavilla J.

Hematol J. 2000;1(1):28-36.

PMID:
11920166
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk